Oncology

Jim Barlow of Geneos Therapeutics explains the role of value networks and strategies to increase cell therapy access.

FDA approves cabozantinib to treat patients with hepatocellular carcinoma, a community in need of new therapeutic options.

How Horizon BCBSNJ’s Episodes of Care program engages physicians in certain specialties in the value-based continuum.

IO therapies hold great promise, but often come with high price tags. How do payers feel about these medications?

The biggest drug categories and medications set for approval this year.

 A new non-small cell lung cancer (NSCLC) treatment is available to healthcare providers immediately.  

Walgreens' new integrated support program aims to help patients with cancer manage the side effects of undergoing treatment. Here’s five things to know about it.

New research from Cardinal Health Specialty Solutions has surprising findings about oncologists from meeting MACRA requirements to burnout.

Here are the top 2 novel cancer drugs cleared by the agency.

As immunotherapy breaks through in cancer therapy, here are five things to know about this promising treatment.

How Froedtert Hospital achieves success with a 24/7/365 cancer clinic.

Dealing with cancer is challenging enough for patients and providers. But even when their different perspectives are factored in, that’s not the whole story.

Cancer medication spending is unsustainable, but significant savings can be achieved just by reducing waste. Here’s how.

Experts predict what oncology care will look like a decade from now.

A Wamberg Genomic Advisors’ Cancer Survey has revealing findings from people dealing directly with cancer.

As lymphoma treatments become less cookie-cutter and more custom, the Leukemia & Lymphoma Society Chief Medical Officer Gwen Nichols, MD, shares how healthcare executives need to alter their approach to managing therapy regimens to increase cure rates and survivorship.

The ability of an oncology practice to succeed in the OCM varies depending on this key factor, according to Avalere research.

New cancer drugs continue to offer patients hope. Here are eight of them.

This year has been another year full of oncology approvals, proving that the oncology pipeline is robust with first-of-the kind molecules, competitor products for existing agents, and biosimilars.

Ochsner Health System’s brings early-stage clinical trials to the Gulf South region.

Here are the top 3 new approvals from FDA.

New cancer developments and research can be challenging to sort through. Here are four misconceptions about cancer that you should know.

A stepwise approach can be best. Here are seven rules to follow.

Payers struggle to determine the appropriate criteria for covering innovative treatments and providers want to increase patient access. Patients’ lives can hang in the balance.

Onboarding new oncology patients can be a delicate process to help them prepare for their care journey. Here are the first steps.